|
|
Regulation Market Research Reports
 | |  |
| |
We offer market research, industry forecasts, and business analysis in the Regulation Market as well as other vertical industries. GII sells reports, databases, newsletters and annual information services that provide the latest market data, such as industry forecasts, projections, trends, market shares, research and development, sales and marketing strategies, and competitive analysis.
|
|
 | |  |
| Pharma and Medical Device Regulatory Affairs |
|
| Table of Contents Published: 2010/02 Price: US $ 7695 Published by: Cutting Edge Information |
| Regulatory teams save time and money as they drive commercial and development goals forward. Build healthy relationships with - and receive clear direction from - regulatory agencies through early, consistent communication. ... |
| Consumer Choices in Healthcare - US - January 2010 |
|
| Table of Contents Published: 2010/01 Price: US $ 3995 Published by: Mintel International Group Ltd, |
| The Great Recession, high unemployment rates, rising premiums, an aging population, and more are changing the face of healthcare in America. Providers in the category must understand these challenges and appropriate responses if they are to flourish. ... |
| China Pharmaceutical Regulatory Report 2010 |
|
| Table of Contents Published: 2010/01 Price: US $ 750 Published by: Pacific Bridge Medical |
| This report includes a brief overview of the pharmaceutical and healthcare industry in China, as well as a discussion of all the relevant laws and regulations that govern the testing, registration, manufacture, import, marketing, and sale of pharmaceutica ... |
| Healthcare Regulatory Update: The United Arab Emirates |
|
| Table of Contents Published: 2010/01 Price: US $ 3800 Published by: Datamonitor |
| The fragmented nature of the healthcare systems in the United Arab Emirates remains despite the implementation of health reforms in the emirates of Abu Dhabi and Dubai. The two major emirates are currently at different stages in the development and implem ... |
| The Pharmaceutical Market: South Korea |
|
| Table of Contents Published: 2010/01 Price: US $ 1040 Published by: Espicom Business Intelligence |
| With a comprehensive health insurance system that covers the entire population South Korea' s pharmaceutical expenditure has risen steadily over the years. This report is ideal for executives wanting to understand the key drivers in the pharmaceutical mar ... |
| Emerging Markets Series: Indonesia and Philippines |
|
| Table of Contents Published: 2009/10 Price: US $ 7600 Published by: Datamonitor |
| As the developed markets are becoming increasingly mature, Pharma is turning to the emerging markets, where long-term growth can be sustained. Of particular interest are Indonesia and the Philippines, which are currently going through major reforms to exp ... |
| Chinese Pharmaceutical Market Outlook 2009-2024 |
|
| Table of Contents Published: 2009/08 Price: US $ 2502 Published by: Visiongain |
| This report - Chinese Pharmaceutical Market Outlook 2009-2024 - analyses prospects for the pharma market and industry sector in China. This new study discusses market drivers and restraints such as production capacity, intellectual property rights and the ... |
| Slovenia Pharmaceuticals and Healthcare Report Q4 2009 |
|
| Table of Contents Published: 2009/08 Price: US $ 875 Published by: Business Monitor International |
| Slovenia is ranked in 9th position in BMI's Business Environment Ratings for Central and Eastern
Europe (CEE) in Q409, highlighting it as a reasonably attractive investment opportunity for drugmakers. ... |
| Serbia Pharmaceuticals and Healthcare Report Q4 2009 |
|
| Table of Contents Published: 2009/08 Price: US $ 875 Published by: Business Monitor International |
| In the BMI's Q409 Business Environment Rating (BER) matrix, Serbia continued to improve its
placement, and is now found in 9th position, out of the 20 key markets surveyed in the Emerging Europe
region. ... |
| Oman Pharmaceuticals and Healthcare Report Q4 2009 |
|
| Table of Contents Published: 2009/08 Price: US $ 875 Published by: Business Monitor International |
| In the Q409 BMI's Business Environment Ranking (BER) matrix for Middle East and Africa
(MEA), Oman is placed seventh, having improved its position by three places in relation to the
previous quarter. ... |
| Hungary Pharmaceuticals and Healthcare Report Q4 2009 |
|
| Table of Contents Published: 2009/08 Price: US $ 875 Published by: Business Monitor International |
| In BMI's Business Environment Ratings (BER) for Q409, Hungary remains ranked 11th, out of the 20
major markets within Central and Eastern Europe (CEE), its position having worsened in recent months. ... |
| Nigeria Pharmaceuticals and Healthcare Report Q4 2009 |
|
| Table of Contents Published: 2009/08 Price: US $ 875 Published by: Business Monitor International |
| For BMI's Q409 Nigeria Pharmaceutical and Healthcare report, we expect total drug market spending in
the country to rise from US$633mn in 2008 to US$695mn by 2013, representing a compound annual
growth rate (CAGR) of 1.59% in US dollar terms and 3.24% i ... |
| Jordan Pharmaceuticals and Healthcare Report Q4 2009 |
|
| Table of Contents Published: 2009/08 Price: US $ 875 Published by: Business Monitor International |
| BMI's new Pharmaceutical & Healthcare Report for Q409 forecasts that the value of the Jordanian drug
market will increase from around JOD263mn (US$370mn) in 2008 to JOD369mn (US$519mn) by 2013. ... |
| Bangladesh Pharmaceuticals and Healthcare Report Q4 2009 |
|
| Table of Contents Published: 2009/08 Price: US $ 875 Published by: Business Monitor International |
| Of the 15 key markets surveyed in BMI's Pharmaceuticals & Healthcare Business Environment
Rankings, Bangladesh is placed in 14th position, and can be found above Vietnam, the latter being judged
the least attractive proposition for investment. ... |
| Australia Pharmaceuticals and Healthcare Report Q4 2009 |
|
| Table of Contents Published: 2009/08 Price: US $ 875 Published by: Business Monitor International |
| In 2008, Australia's pharmaceutical market was worth US$6.93bn, it is forecast to reach US$7.28bn in
2009 and rise to over US$10bn in 2013, which represents a compound annual growth rate (CAGR) of
7.72. ... |
| The Pricing and Reimbursement Environment for Neurology Drugs |
|
| Table of Contents Published: 2009/08 Price: US $ 2300 Published by: Decision Resources, Inc. |
| Neurological disorders will impose a growing social and fi nancial burden on the major pharmaceutical markets as the elderly population in these countries increases steadily. Governments and other payers recognize the pressing need to tackle these disease ... |
| The Executive Guide to Worldwide Healthcare Organisation |
|
| Table of Contents Published: 2009/08 Price: US $ 515 Published by: Espicom Business Intelligence |
| Barack Obama' s plans for healthcare reform in the US have generated a great deal of controversy, with opponents appalled at what they see as an increasing tax burden and over involvement of the state. In contrast, the UK' s NHS provides a comprehensive s ... |
| Pricing and Reimbursement: Innovative Risk-Sharing Strategies |
|
| Table of Contents Published: 2009/07 Price: US $ 3800 Published by: Datamonitor |
| Novel niche biologics entering the market require high price points in order to provide manufacturers with a return on investment. However, with heightening regulatory scrutiny and increasing cost-pressures, a balance must be struck between incentivizing ... |
| Russia Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/07 Price: US $ 875 Published by: Business Monitor International |
| Russia's overall macroeconomic situation has stabilised markedly since the end of Q109 - most notably
as the ruble's managed devaluation earlier in the year did not turn into a rout for the currency, or consume
all of the country's stability fund. Still ... |
| China Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/07 Price: US $ 875 Published by: Business Monitor International |
| For the Q309 update of BMI's China Pharmaceuticals & Healthcare report, we have maintained our topline
forecast for medicine expenditure in the world's most populous country, as no new sales figures have
emerged and the country's macroeconomic projectio ... |
| The SADC Healthcare Regulatory Environment |
|
| Table of Contents Published: 2009/07 Price: US $ 6000 Published by: Frost & Sullivan |
| This research service identifies and discusses the regulatory framework (including that of medical waste management and medical insurance) of the Southern African Development Communities (SADC) countries. ... |
| Spain Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/07 Price: US $ 875 Published by: Business Monitor International |
| Spainfs pharmaceutical market, valued at EUR15.3bn in 2008, is expected to be cushioned from the
impact of the global financial crisis in the short term, with BMI forecasting nominal drug market
expenditure growth of 6% in euros between 2008 and 2009. ... |
| Slovenia Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/06 Price: US $ 875 Published by: Business Monitor International |
| In BMI's Business Environment Ranking table adjusted for Q309, Slovenia continued to improve its
position in the Central and Eastern European (CEE) matrix and ranks 9th, up from 11th and 12th in the
previous two quarters respectively. ... |
| Zimbabwe Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/06 Price: US $ 875 Published by: Business Monitor International |
| In the BMI Business Environment Ranking for Q309, Zimbabwe remains firmly at the bottom of the
matrix, which ranks 17 key markets surveyed in the Middle East and Africa (MEA) region, as well as
globally. Zimbabwefs position is expected to show little i ... |
| Thailand Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/06 Price: US $ 875 Published by: Business Monitor International |
| In BMIfs Pharmaceutical Environment Ranking table for Q309, Thailand remains placed 10th, out of the
15 key markets surveyed in the Asia Pacific region. Thailandfs growing and ageing population and the
expansion of universal healthcare coverage repres ... |
| Slovakia Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/06 Price: US $ 875 Published by: Business Monitor International |
| Following an update to our macroeconomic variables as a result of both the eurozone accession and
global economic downturn, BMI now expects Slovakiafs pharmaceutical expenditure to grow to
EUR2.06bn (US$2.62bn) by 2013. While this is below our previous ... |
| Singapore Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/06 Price: US $ 875 Published by: Business Monitor International |
| In BMIfs Business Environment Rankings (BER) matrix for Q309, Singapore slipped from fourth to
sixth position out of the 15 key countries in the Asia Pacific region, in line with worsening economic
conditions and their impact on the pharmaceutical mark ... |
| Philippines Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/06 Price: US $ 875 Published by: Business Monitor International |
| The Philippines remains ranked as the 11th most attractive pharmaceutical market among 15 major
countries in the Asia Pacific region, according to BMIfs Business Environment Rankings for Q309.
Nevertheless, BMI expects the country to improve this posit ... |
| Lebanon Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/06 Price: US $ 875 Published by: Business Monitor International |
| Lebanon remains a strong pharmaceutical market in the Middle East and Africa (MEA) region. In BMIfs
updated Business Environment Ratings for Q309, Lebanon holds a respectable 13th position. The
countryfs pharmaceutical market was worth US$500mn in 200 ... |
| Latvia Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/06 Price: US $ 875 Published by: Business Monitor International |
| BMI calculates the Latvian pharmaceutical market to have been worth LVL256mn (US$512mn) in 2008,
and by 2013, drug expenditure is expected to reach a value of LVL352mn. In US dollar terms, however,
as a result of the weakening lat, drug market spending ... |
| Kuwait Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/06 Price: US $ 875 Published by: Business Monitor International |
| Kuwait's pharmaceutical market is small in regional terms. Combined sales of over-the-counter (OTC)
and prescription drugs reached a total of US$377mn in 2008, and we expect this to reach US$462mn by
2013 - representing a compound annual growth rate (CA ... |
| Israel Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/06 Price: US $ 875 Published by: Business Monitor International |
| In BMIfs updated Business Environment Rankings (BER) for Q309, Israel continued slipping down the
table, now ranking seventh out of the 17 Middle East and African (MEA) markets surveyed. While the
country scores strongly across the country structure an ... |
| Greece Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/06 Price: US $ 875 Published by: Business Monitor International |
| Greecefs uncontrolled growth in drug expenditure, which increased by 59% between 2004 and 2008, has
led the country to rank among the highest per capita spenders in Europe. While a proportion of this figure
is likely attributable to the countryfs para ... |
| Germany Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/06 Price: US $ 875 Published by: Business Monitor International |
| Germany's drug market expenditure reached a value of EUR40.6bn (US$59.7bn) in 2008. The value of
the country's pharmaceutical market is forecast to reach EUR48.6bn (US$61.6bn) by 2013, representing a
compound annual growth rate (CAGR) of 3.69% in local ... |
| Croatia Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/06 Price: US $ 875 Published by: Business Monitor International |
| Of the 20 markets measured in BMIfs Q309 Pharmaceuticals & Healthcare Business Environment
Rankings for Central and Eastern Europe (CEE), Croatia is placed 10th, reflecting the countryfs middleranking
attractiveness for multinational companies. While ... |
| Canada Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/06 Price: US $ 875 Published by: Business Monitor International |
| For BMIfs Pharmaceutical and Healthcare Q309 Report for Canada, we believe the total drug market
value will increase from US$22.4bn in 2008 to US$37.2bn by 2013, representing a compound annual
growth rate (CAGR) of 10.7% in US dollar terms. We believe ... |
| Bangladesh Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/06 Price: US $ 875 Published by: Business Monitor International |
| Out of the 15 key markets surveyed in BMIfs Pharmaceuticals & Healthcare Business Environment
Rankings, Bangladesh is placed in 13th position, and can be found above Pakistan and Vietnam, the latter
being judged the least attractive proposition for inv ... |
| Pakistan Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/06 Price: US $ 875 Published by: Business Monitor International |
| Pakistan' s pharmaceutical expenditure was valued at PKR127bn (US$2bn) in 2008. Between 2009 and
2013, BMI forecasts that the market should grow at a nominal CAGR of 12.7% in local currency to reach
PKR230bn (US$3bn) in 2013, with population growth bein ... |
| Nigeria Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/06 Price: US $ 875 Published by: Business Monitor International |
| In BMI' s Q309 update of the Pharmaceutical Business Environment Rankings for the Middle East and
Africa (MEA) region, Nigeria is once again ranked second-last out of the 17 key regional markets, above
only Zimbabwe. Globally, Nigeria is also ranked sec ... |
| Kenya Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/06 Price: US $ 875 Published by: Business Monitor International |
| BMI calculates Kenya' s pharmaceutical expenditure to have been KES15.85bn (US$229mn) in 2008. By
2013, we expect the total amount spent on prescription and over-the-counter (OTC) medicines to have
reached a value of KES29.89bn (US$395mn) equating to a ... |
| Jordan Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/06 Price: US $ 875 Published by: Business Monitor International |
| BMI has revised its extended forecast for Jordan' s pharmaceutical and healthcare market for our Q309
report. We expect the total drug market to grow from US$370mn in 2008 to US$519mn by 2013,
representing a compound annual growth rate (CAGR) of 7.01%. ... |
| Iran Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/06 Price: US $ 875 Published by: Business Monitor International |
| For BMI' s Q309 Iran Pharmaceutical and Healthcare Report, we expect a 9.0% compound annual growth
rate (CAGR) for the total pharmaceutical market, meaning an increase in total value from US$2.27bn in
2008 to US$3.50bn by 2013. We believe the main drive ... |
| Australia Pharmaceuticals and Healthcare Report Q3 2009 |
|
| Table of Contents Published: 2009/06 Price: US $ 875 Published by: Business Monitor International |
| In 2008, Australia' s pharmaceutical market was worth US$7bn. BMI expects the pharma industry to post
modest growth over the forecast period, with a CAGR of 3.2% between 2008-2013, in local currency
terms. Growth will be largely due to the market' s hig ... |
| Emerging Markets Series: The Pharmaceutical Market of Poland |
|
| Table of Contents Published: 2009/06 Price: US $ 5700 Published by: Datamonitor |
| Poland' s economy has grown from strength to strength in the past 5 years, and despite the global economic downturn Poland is expected to maintain positive growth through 2010. However, concern exists over intellectual property and inconsistent drug reimb ... |
|
| The Outlook for Pharmaceuticals in Latin America |
|
| Table of Contents Issues / Year: 4 Price: US $ 3490 Published by: Espicom Business Intelligence |
| The region, led by Brazil, is better prepared to face global instability than in the past but economic growth is expected to slow down, after a recent period of remarkable growth. Access to medicines in the public sector has increased, particularly among ... |
| The Outlook for Pharmaceuticals in Western Europe |
|
| Table of Contents Price: US $ 3490 Published by: Espicom Business Intelligence |
| Market growth in the mature markets of Western Europe is assured over the coming years by the health needs of ageing populations, and will be driven by investment in innovative medicines, particularly in the hospital market.
Growth in the mature pharm ... |
|
|
|
View Cart
